Log in

NASDAQ:FGENFibroGen Stock Price, Forecast & News

$32.57
-1.47 (-4.32 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$31.65
Now: $32.57
$34.42
50-Day Range
$23.30
MA: $37.16
$45.70
52-Week Range
$22.65
Now: $32.57
$55.63
Volume349,586 shs
Average Volume919,776 shs
Market Capitalization$2.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Read More
FibroGen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$256.58 million
Book Value$6.14 per share

Profitability

Net Income$-76,970,000.00

Miscellaneous

Employees461
Market Cap$2.87 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.


FibroGen (NASDAQ:FGEN) Frequently Asked Questions

How has FibroGen's stock been impacted by COVID-19 (Coronavirus)?

FibroGen's stock was trading at $35.40 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FGEN stock has decreased by 8.0% and is now trading at $32.57. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of FibroGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for FibroGen.

When is FibroGen's next earnings date?

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for FibroGen.

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) issued its earnings results on Monday, March, 2nd. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.53. The biopharmaceutical company earned $7.97 million during the quarter, compared to analysts' expectations of $40.32 million. FibroGen had a negative return on equity of 13.35% and a negative net margin of 30.00%. The business's quarterly revenue was down 92.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.23 EPS. View FibroGen's earnings history.

What price target have analysts set for FGEN?

5 equities research analysts have issued 12-month price targets for FibroGen's stock. Their forecasts range from $40.00 to $72.00. On average, they expect FibroGen's stock price to reach $52.00 in the next year. This suggests a possible upside of 59.7% from the stock's current price. View analysts' price targets for FibroGen.

Has FibroGen been receiving favorable news coverage?

News stories about FGEN stock have been trending very negative on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. FibroGen earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutFibroGen.

Are investors shorting FibroGen?

FibroGen saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 5,390,000 shares, a decline of 7.7% from the February 13th total of 5,840,000 shares. Based on an average daily volume of 612,100 shares, the short-interest ratio is currently 8.8 days. Approximately 6.7% of the shares of the stock are short sold. View FibroGen's Current Options Chain.

Who are some of FibroGen's key competitors?

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), ALJ Regional (ALJJ) and Allergan (AGN).

Who are FibroGen's key executives?

FibroGen's management team includes the following people:
  • Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
  • Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)
  • Dr. K. Peony Yu, Chief Medical Officer (Age 57)
  • Mr. Julian N. Stern, Sec. (Age 94)
  • Dr. Barry A. Berkowitz, Founder

When did FibroGen IPO?

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a number of institutional and retail investors. Top institutional investors include Woodstock Corp (0.03%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View institutional ownership trends for FibroGen.

Which major investors are buying FibroGen stock?

FGEN stock was acquired by a variety of institutional investors in the last quarter, including Woodstock Corp. View insider buying and selling activity for FibroGen.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $32.57.

How big of a company is FibroGen?

FibroGen has a market capitalization of $2.87 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe. View additional information about FibroGen.

What is FibroGen's official website?

The official website for FibroGen is http://www.fibrogen.com/.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel